CD160 Antibody Pair [HRP]

Name: CD160 Antibody Pair [HRP]
Brand: Novus Biologicals
SKU: NBP2-79391
Price: 969 USD
Availability: InStock

Novus Biologicals | Catalog # NBP2-79391

Submit a review

Product Documents

Recombinant Monoclonal Antibody

100% Guarantee

Product Specifications
Scientific Data
Kit Contents
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Assay Type

Sandwich ELISA

Assay Range

93.75-6000 pg/ml (example only; lot dependent)

Sensitivity

93.75 pg/ml (example only; lot dependent)

Reactivity

Human

View all CD160 ELISA Kits »

Product Specifications

Description

Solid Phase sandwich ELISA for the quantitative determination of Human CD160.

Sample Volume Required

100 ul

Conjugate

HRP

Scientific Data Images for CD160 Antibody Pair [HRP]

Sandwich ELISA: CD160 Antibody Pair [HRP] [NBP2-79391] - This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.

Kit Contents for CD160 Antibody Pair [HRP]

Rabbit Monoclonal Capture Antibody: (Catalog # NBP2-90073)
Rabbit Monoclonal Detection Antibody (HRP-conjugated): (Catalog # NBP2-90072)
Standard

Preparation and Storage

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: CD160

CD160, also known as BY55 and NK1, belongs to a class of natural killer (NK) receptors known as the major histocompatibility complex (MCH) class I-dependent NK cell activating receptor (1). CD160 exists as either a glycosylphosphatidylinositol (GPI)-anchored isoform or a transmembrane protein and is expressed on NK cells and cytotoxic T lymphocytes, as well as endothelial cells (1-3). CD160 has both stimulatory and inhibitory receptor functions and regulates cell differentiation and activation (2). The human CD160 protein is 181 amino acids (aa) in length with a theoretical molecular weight (MW) of 19.8 kDa (2,3). However, given that the CD160 protein is subject to glycosylation, addition of disulfide bonds, lipidation, and propitiation, the observed MW is often much higher (2). The human CD160 protein consists of a single immunoglobulin (Ig)-like domain (25-133 aa) and does not contain any immunoreceptor tyrosine-based activation motifs (ITSMs) (2). Thus, CD160 requires the recruitment of adaptor proteins such as phosphoinositide-3 kinase (PI3K) to promote cytotoxic functions including cytokine secretion (1,3).

Identified ligands for CD160 include MHC class I proteins and herpes virus entry mediators (HVEM), each of which has a different effect on NK or T cells (1,3-5). CD160 binds to MHC class I proteins with weaker affinity, but the interaction causes NK cell cytotoxic function and cytokine production (1,3). CD160 engagement of MHC class I proteins and/or HVEM within NK cells promotes ERK1/2 and AKT activation and production of interferon gamma (IFNgamma) (5). Conversely, CD160 binding of HVEM in CD4+ T cells induces inhibitory signaling, signifying both a stimulatory and inhibitory role for CD160 as well as cell-specific context (4,5). Additionally, CD160 plays a role in diseases including certain types of cancer, such as thyroid cancer and colon cancer, viral infections, and autoimmune diseases (3,5). CD160 expression levels on CD8+ T cells have been shown to be elevated in chronic viral infections such as human immunodeficiency virus (HIV) and Epstein Barr virus (EBV) (3). In addition, when CD160 is co-expressed with the programmed cell death protein 1 (PD-1) receptor, T cell exhaustion occurs due to persistent stimulation, leading to inhibited immune response and ability to combat infection (3). CD160 may be a promising therapeutic target in cancer as murine studies have demonstrated that blocking the CD160-HVEM pathway causes a regression of neoplastic tumors in a thyroid cancer model (3-5).

References

1. Le Bouteiller P, Tabiasco J, Polgar B, et al. CD160: a unique activating NK cell receptor. Immunol Lett. 2011;138(2):93-96. https://doi.org/10.1016/j.imlet.2011.02.003

2. Uniprotkb (O95971)

3. Piotrowska M, Spodzieja M, Kuncewicz K, Rodziewicz-Motowidlo S, Orlikowska M. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem. 2021;224:113694. https://doi.org/10.1016/j.ejmech.2021.113694

4. Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev. 2009;229(1):244-258. https://doi.org/10.1111/j.1600-065X.2009.00783.x

5. Sedy JR, Ramezani-Rad P. HVEM network signaling in cancer. Adv Cancer Res. 2019;142:145-186. https://doi.org/10.1016/bs.acr.2019.01.004

Alternate Names

BY55, CD160, NK1, NK28

Gene Symbol

CD160

Additional CD160 Products

Product Documents for CD160 Antibody Pair [HRP]

Download Product Datasheets

Download Manual - CD160 Antibody Pair [HRP]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for CD160 Antibody Pair [HRP]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Antibody Pairs are guaranteed for 6 months from date of receipt.